Valeant Pharmaceuticals International (NYSE: VRX ) is expected to report Q2 earnings on Aug. 2. Here's what Wall Street wants to see.
The 10-second takeaway
Comparing the upcoming quarter with the prior-year quarter, average analyst estimates predict Valeant Pharmaceuticals International's revenues will grow 35.0% and EPS will expand 35.6%.
The average estimate for revenue is $822.7 million. On the bottom line, the average EPS estimate is $0.99.
Last quarter, Valeant Pharmaceuticals International booked revenue of $856.1 million. GAAP reported sales were 52% higher than the prior-year quarter's $565.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.14. GAAP EPS were -$0.04 for Q1 compared to $0.02 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 67.4%, 730 basis points worse than the prior-year quarter. Operating margin was 20.7%, 710 basis points worse than the prior-year quarter. Net margin was -1.5%, 260 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $3.53 billion. The average EPS estimate is $4.54.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 185 members out of 205 rating the stock outperform, and 20 members rating it underperform. Among 62 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 55 give Valeant Pharmaceuticals International a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Valeant Pharmaceuticals International is outperform, with an average price target of $60.59.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Valeant Pharmaceuticals International the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.